This finding indicates that luminal A-like (ER+ PgR+) BCs, which are characterized by slower tumor cell growth and proliferation rates, could be more sensitive to the CV combination when compared with luminal B-like (ER+ PgR−) BCs. The gene discussed is ESR1; the disease is neoplasm.